Biostax and Immgenuity to expedite HIV immunotherapies development

30 Aug 2023
www.pharmaceutical-technology.com
VaccineImmunotherapyClinical Study
Biostax and Immgenuity to expedite HIV immunotherapies development
Preview
Source: Pharmaceutical Technology
IMTVO14 immunotherapy comprises a genetically modified HIV virus. Credit: Corona Borealis Studio/Shutterstock.com.
Biostax and Immgenuity have entered a research collaboration agreement to expedite the development of new immunotherapeutics to treat HIV and other diseases.
The research will focus on Immgenuity’s IMTV014 vaccine platform and Biostax’s Lodonal and JKB-122, both independently and together.
Recommended Reports
Biostax and Immgenuity to expedite HIV immunotherapies development
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - PENNVAX-GP in Human Immunodeficiency Virus (HIV) Infections (AIDS) GlobalData
Biostax and Immgenuity to expedite HIV immunotherapies development
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Teropavimab in Human Immunodeficiency Virus (HIV) Infections (AIDS) GlobalData
View allCompanies IntelligenceBiostax CorpImmgenuity IncView all
The companies will jointly determine if the immune-modulatory effects of their combined therapies can achieve remission in HIV patients.
Immgenuity president and CEO Dr Sateesh Apte stated: “Remission in HIV remains the ultimate aspiration for both Biostax’s and Immgenuity’s research and development efforts.
“Patients are required to be off all anti-viral medications before Immgenuity’s vaccine platform can be administered and we expect Biostax’s naltrexone-based drug candidates to work synergistically during the period when patients stop taking their anti-viral medications and before the vaccine’s immune response takes effect.
“This, along with Biostax’s immune-modulating therapy and our other partnerships and internal programmes, reflects our commitment to finding a therapy that will achieve remission for HIV and bring about an end to the HIV epidemic.”
IMTVO14 immunotherapy comprises a genetically modified HIV virus that restores immune signalling to provide a robust immune response to HIV.
It was found to be safe in preclinical studies for treating HIV and NeuroAIDS.
Biostax CEO Noreen Griffin stated: “Based upon existing HIV data surrounding both JKB-122 and Lodonal, we believe that by performing combined research we will generate additional compelling data, that complements our existing clinical data.
“We are delighted to enter into this partnership that will further develop our product candidates for the treatment of patients with HIV.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.